The short answer
Avoid adding kava to alprazolam without prescriber review. Official kava guidance advises against combining it with sedatives, and an exact-pair case report is indexed, although its full details were not accessible here.
What this answer covers
Oral Piper methysticum; dose, extract and other CNS depressants matter.
- Supplement or preparation
- Piper methysticum
- Medication ingredient
- alprazolam
Why the precaution applies
NCCIH advises against kava with sedatives. Alprazolam labeling recognizes additive CNS depression with other depressants, so this combination needs clinician review.
What the case report can and cannot show
A published case report is titled as coma involving kava and alprazolam. Its full clinical details were not available for this review, so it cannot establish the exact dose, other contributing drugs or how often this occurs.
Do not use timing as a workaround
No reliable separation interval has been established. Describe regular or heavy kava use and all other sedatives to the prescriber when planning changes.
Protect your alertness
Alprazolam can impair coordination and alertness. Avoid driving when affected. Seek urgent help for severe difficulty waking or breathing, and tell the prescriber about all other sedating medicines and alcohol.
Evidence and practical considerations
Side effects & toxicity
Conditional avoidance follows authoritative sedative co-use guidance and alprazolam labeling, not a fabricated reconstruction of a case report.
- Exact scope
- Oral Piper methysticum; dose, extract and other CNS depressants matter. with Exact oral alprazolam; no blanket benzodiazepine metabolic or route transfer.
- Medication form and route
- oral; other cannabis routes only if explicitly discussed
- Timing or duration
- Exact duration and dose depend on source; single-dose and chronic use are distinguished.
What remains uncertain
- Original case has no abstract; full text returned 403. No controlled exact combination trial or safe interval.
Factors that may matter: preparation and plant part; dose; other medicines; baseline alertness; clinical indication.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral alprazolam.
CNS depression, impaired coordination and alertness can occur; concomitant CNS depressants require caution. Dependence and withdrawal risks require individualized tapering rather than abrupt cessation. Metabolism involves CYP3A; inhibitors and inducers may alter exposure. Not the same metabolic pathway profile as oxazepam or temazepam.
How this applies: Exact RxNorm ingredient and oral formulation confirmed in original label; use exact indication and metabolic boundaries.
Does not quantify the requested botanical interaction risks, prove every herb is sedating, or establish a protective supplement interval.
Source 2: official guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: People considering the specified supplement.
Advises against use with sedative substances. Kava may cause dizziness and has been linked to rare severe liver injury, including with different extraction methods.
How this applies: Preparation-specific context; not a directly measured alprazolam interaction.
Not a alprazolam study. Intrinsic liver risk does not establish added alprazolam hepatotoxicity; preparation and co-exposure vary.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Indexed 1996 case report.
Bibliographic record confirms a reported coma case; no abstract available.
How this applies: Apply only to exact medication, preparation and study exposure; comparator treatment is not co-use.
Original full text access attempt returned 403. Patient regimen, co-exposures and causality not independently established; title alone is not clinical proof.
Source 4: randomized placebo-controlled trial
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 391 adults randomized to three groups in an internet-based trial.
Neither active intervention improved its primary anxiety or insomnia outcome more than placebo.
How this applies: Preparation-specific context; not a directly measured alprazolam interaction.
Not both active botanicals together, not alprazolam co-use. Accessible abstract does not fully characterize dose and preparation; efficacy result is not proof of combination safety.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Current exact claims adjudicated against captured originals and explicit comparator/co-use boundaries. | |
| Research summary published |
Article revision: 71df483843b29bcc
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.